Shaken MorphoSys ‘Assessing Options’ After Losing US Darzalex Patent Ruling
Executive Summary
But German Biotech says court summary judgement will have no bearing on MorphoSys's own CD38 antibody MOR202.
You may also be interested in...
Building A Biotech: Industry Veteran Moroney Reflects
Simon Moroney has led the German antibody technology biotech MorphoSys since 1992. Having taken the decision to retire just as the firm is entering the next phase in its evolution, he explains to Scrip why the time is right.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.